Filter posts

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

Jim Greenwood Talks 21st Century Cures with Chairman Fred Upton

Recently, BIO CEO and President Jim Greenwood sat down with House Energy and Commerce Chairman …

The Cancer Death-Panel App

In an article for the New York Post, Robert Goldberg, vice president of the Center …

AIR 340B New Report: Contract Pharmacy Growth in 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …

Is Regulatory Transformation for Alzheimer’s Therapies Needed?

BIO 2014’s  session titled ” Regulatory Transformation: As Alzheimer’s Disease Science, Research and Advocacy Move …

Exchange Plans are Helping Patients, But Challenges Remain

After describing many of the benefits the Exchanges have brought to patients—including access to both …

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading …

Gates Foundation Issues Biotech Call to Action

Today, Trevor Mundel from the Bill & Melinda Gates Foundation discussed the untapped potential of …